Sungen Biomed

Sungen Pharma is a specialty pharmaceutical company focused on the development, manufacturing, and commercialization of high-barrier generic and innovative 505(b)(2) products. Headquartered in Monmouth Junction, New Jersey, the company specializes in complex dosage forms, including injectables, ophthalmics, and topicals. Sungen Pharma maintains a robust pipeline of over 20 products targeting therapeutic areas such as pain management, ophthalmology, and endocrinology. In 2020, the company was acquired by Grand Pharmaceutical Group, a major international pharmaceutical company, to serve as its R&D and manufacturing hub in the United States. The company operates a cGMP-compliant facility and leverages its expertise in formulation and regulatory affairs to bring cost-effective medications to the global market.